Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions
JL Huo, Q Feng, S Pan, WJ Fu, Z Liu, Z Liu - Cell death discovery, 2023 - nature.com
Diabetic cardiomyopathy (DCM) mainly refers to myocardial metabolic dysfunction caused
by high glucose, and hyperglycemia is an independent risk factor for cardiac function in the …
by high glucose, and hyperglycemia is an independent risk factor for cardiac function in the …
Mitochondrial transplantation: opportunities and challenges in the treatment of obesity, diabetes, and nonalcoholic fatty liver disease
Y Chen, F Yang, Y Chu, Z Yun, Y Yan, J Jin - Journal of Translational …, 2022 - Springer
Metabolic diseases, including obesity, diabetes, and nonalcoholic fatty liver disease
(NAFLD), are rising in both incidence and prevalence and remain a major global health and …
(NAFLD), are rising in both incidence and prevalence and remain a major global health and …
Phosphodiesterases in heart and vessels-From Physiology to Diseases
Q Fu, Y Wang, C Yan, YK Xiang - Physiological Reviews, 2023 - journals.physiology.org
Phosphodiesterases (PDEs) are a superfamily of enzymes that hydrolyze cyclic nucleotides,
including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate …
including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate …
Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: from fundamental research to therapy
XJ Zhang, XW Han, YH Jiang, YL Wang, XL He… - International …, 2023 - Elsevier
Diabetic cardiomyopathy (DCM) is a prevalent cardiovascular complication of diabetes
mellitus, characterized by high morbidity and mortality rates worldwide. However, treatment …
mellitus, characterized by high morbidity and mortality rates worldwide. However, treatment …
Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction …
Background Treatment with phosphodiesterase type 5 inhibitors (PDE-5is) is effective in
treating erectile dysfunction (ED). Aim The objective of this study was to determine the effect …
treating erectile dysfunction (ED). Aim The objective of this study was to determine the effect …
Serum trimethylamine-N-oxide is associated with incident type 2 diabetes in middle-aged and older adults: a prospective cohort study
S Li, S Chen, X Lu, A Fang, Y Chen, R Huang… - Journal of Translational …, 2022 - Springer
Background The role of trimethylamine-N-oxide (TMAO) in the development of diabetes
remains controversial, and prospective data are few. We aimed to investigate the …
remains controversial, and prospective data are few. We aimed to investigate the …
[HTML][HTML] The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders
Platelets are the “guardians” of the blood circulatory system. At sites of vessel injury, they
ensure hemostasis and promote immunity and vessel repair. However, their uncontrolled …
ensure hemostasis and promote immunity and vessel repair. However, their uncontrolled …
Inflammatory plasma proteins predict short-term mortality in patients with an acute myocardial infarction
T Schmitz, E Harmel, M Heier, A Peters… - Journal of translational …, 2022 - Springer
Background The aim of this study was to investigate the association between inflammatory
markers and 28-day mortality in patients with ST-elevation myocardial infarction (STEMI) …
markers and 28-day mortality in patients with ST-elevation myocardial infarction (STEMI) …
Sex bias in immune response: it is time to include the sex variable in studies of autoimmune rheumatic diseases
LI Sakkas, IC Chikanza - Rheumatology International, 2024 - Springer
Healthy females and males differ in their immune cell composition and function and females
generally mount stronger immune response than males and are much more susceptible to …
generally mount stronger immune response than males and are much more susceptible to …
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics
D Stehle, M Barresi, J Schulz, R Feil - Pharmacology & Therapeutics, 2023 - Elsevier
The second messenger cyclic guanosine monophosphate (cGMP) is an important regulator
of human (patho-) physiology and has emerged as an attractive drug target. Currently, cGMP …
of human (patho-) physiology and has emerged as an attractive drug target. Currently, cGMP …